Aktie A3DR6E MIND MEDICINE (MINDMED) INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Mind Medicine (MindMed) Inc.

Aktien

A3DR6E

CA60255C8850

MNMD

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 27.06.2024 		% 5 Tage % 1. Jan.
7,25 USD -0,28 % Intraday Chart für Mind Medicine (MindMed) Inc. 0,00 % +98,09 %
20.06. Mind Medicine (MindMed) Inc. gibt konstruktives End-of-Phase 2 Meeting mit der U.S. FDA für MM120 bei generalisierter Angststörung (GAD) bekannt CI
05.06. Sektor-Update: Aktien des Gesundheitswesens am Mittwoch vorbörslich stabil MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Mind Medicine Inc.(NasdaqGS:MNMD) added to S&P Pharmaceuticals Select Industry Index
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
Mind Medicine Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder
MindMed ICPR 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
Sector Update: Health Care Stocks Steady Premarket Wednesday
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Top Premarket Decliners
MindMed to Participate in June Conferences
Mind Medicine (MindMed) Inc. - New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting Show Growing Burden and Impact of Generalized Anxiety Disorder in the US
MindMed to Participate at May Investor Conferences
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
Mind Medicine Inc. Announces the Departure of Schond Greenway as Chief Financial Officer
MindMed Reports First Quarter 2024 Financial Results and Business Updates
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States
MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States
MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DR6E Aktie
  4. Nachrichten Mind Medicine (MindMed) Inc.
  5. Andere Sprachen